Skip to main content

Table 1 Characteristics of the included studies

From: Disease severity, debridement approach and timing of drug modify outcomes of adjunctive azithromycin in non-surgical management of chronic periodontitis: a multivariate meta-analysis

Author/Year

n/ Country

n (Female/Male)

Age (years)

Project Design

Intervention Methodology

Nature of S/RSD

Intervention Groups

Follow-Up

Periodontal Maintenance

Adverse Events

Mascarenhas et al. 2005 [28]

30/ USA

AZI: 15 (4/11)

C: 15 (7/8)

AZI: 47.0 ± 10.1

C: 45.3 ± 10.8

Parallel, Single Blinded

AZI: Post therapy, End of S/RSD, in 2 sessions within 14 days

C: S/RSD in 2 sessions within 14 days.

Qu S/RSD(2 sessions)

AZI: 500 g × 1 day + 250 g × 4 days

C: S/RSD

3, 6 months from baseline

3rd, 6th months by examiner

Not reported

Gomi et al. 2007 [25]

34/ Japan

AZI: 17 (9/8)

C: 17 (9/8)

AZI: 45.4 ± 14.3,

C: 51.0 ± 8.8,

not described

AZI: Pre-therapy, 3 days prior to S/RSD

C: S/RSD in 4–6 times, weekly intervals

FMD

AZI: 500 g × 3 days

C: S/RSD

1, 3, 6 months from baseline

Weekly by Dental Hygienist

Diarrhoea (n = 1)

Haffajee et al. 2007 [32]

48/ USA

AZI: 25 (10/15),

C: 23 (7/16)

AZI:47 ± 14,

C:43 ± 15

Parallel. Single Blinded

AZI: Pretherapy,

Start of Quadrant Wise S/RSD

C: S/RSD in 4 weekly intervals

Qu S/RSD (4 sessions)

AZI: 500 g × 3 days

C: S/RSD

1, 3, 6, 12 months from baseline

1st, 3rd, 6th and 12th months

Difficulty in swallowing (n = 1)

Allergic reaction (n = 1)

Yashima et al. 2009 [27]

30/ Japan

AZI 1: 10 (6/4),

AZI 2: 10 (5/5),

C: 10 (4/6)

AZI 1: 51.1 ± 11.6,

AZI 2: 50.8 ± 14.2,

C: 51.0 ± 10.6

not described

AZI 1: Pre therapy

3 days prior to S/RSD (Full Mouth)

AZI 2: Pre therapy

3 days prior to S/RSD. Conducted in 3 times, within 7 days

C: S/RSD in 6 sessions with 1 week interval

FMD

Qu S/RSD (3 sessions)

AZI 1: 500 g × 3 days

AZI 2: 500 g × 3 days

C: S/RSD

1, 3, 6, 9, 12 months from baseline

Once a month by the Dental Hygienist

Diarrhoea (n = 1)

Oteo et al. 2010 [30]

28/ Spain

AZI: 15 (8/7), C: 13 (5/8)

AZM: 46.6,

C: 7.1

Parallel, Double Blind, Placebo Controlled.

AZI: Post therapy,

End of S/RSD in 2 times, within 7 days

C: S/RSD in 2 times, within 7 days.

Qu S/RSD –(2 sessions)

AZI: 500 g × 3 days

C: Placebo ×  3 days

1, 3, 6 months from baseline

1st, 3rd, 6th months

Diarrhoea n = 1)

Sampaio et al. 2011 [34]

40/ Brazil

AZI: 20 (7/13), C: 20 (9/11)

AZI: 44.4 ± 7.42,

C: 43.5 ± 5.90

Parallel, Double Blind, Placebo Controlled

AZI: Post therapy,

End of S/RSD in 4–6 times, within 14 days

C: S/RSD in 4–6 sessions within 14 days

Qu S/RSD (4–6 sessions)

AZI: 500 g × 5 days

C: Placebo ×  3 days

6, 12 months from baseline

Not reported

Diarrhoea (n = 1); Excessive Sleepiness (n = 3)

Headache (n = 1)

Han et al. 2012 [33]

28/ Turkey

AZI: 14 (4/10), C: 14 (6/8)

AZI: 46.8 ± 5.1

C: 44.8 ± 5.0

Parallel, Double Blind, Placebo Controlled

AZI: Post therapy,

End of quadrant by quadrant S/RSD in 4 sessions

C: Quadrant by quadrant S/RSD in 4 sessions

Qu S/RSD (4 sessions)

AZI: 500 g × 3 days

C: Placebo ×  3 days

1, 3, 6 months from baseline

Not Reported

None

Fonseca et al. 2015 [29]

85/ Brazil

AZI 1: 15, C 1: 15

AZI 2: 14, C 2: 13

44.6 ± 8.8

Parallel, double blinded

AZI 1: Pretherapy, Start of full mouth S/RSD.

C 1: Full mouth S/RSD within 24 h in 2 sessions.

AZI 2: Pretherapy, Start of quadrant S/RSD.

C 2: S/RSD per quadrant for 30 min in weekly interval between sessions

1. FMD (2 sessions in 24 h)

2. Qu S/RSD (4 weekly sessions)

AZI:

500 g × 3 days

C: S/RSD alone

3, 6 months from baseline

Not reported

None

Martande et al. 2016 [31]

70/ India

AZI: 35 (14/21), C: 35 (16/19)

AZI: 33.3 ± 7.3

C: 32.6 ± 5.4

Parallel, Double Blind, Placebo Controlled

AZI: Post-therapy

End of S/RSD in 3–5 times within 14 days.

C: S/RSD in 3–5 times within 14 days

Qu S/RSD (3–5 sessions)

AZI: 500 g × 3 days

C: Placebo ×  3 days

1, 3, 6, 12 months from baseline

1st, 3rd, 6th, 12th week

  1. AZI Test group: Azithromycin + S/ RSD Group. C Control Group; SRSD alone, FMD Full mouth debridement, PMD Partial Mouth S/RSD,
  2. (studies are ordered by year of publication)